Intracardiac  injection of Erythropoietin/Hematopoietin protects against cardiac hypertrophy and fibrosis: Intracardiac  injection of erythropoietin/hematopoietin decreases MiR-29 expression, activates wnt- signaling and its components GSK3B, ICAT/CTNNBIP1, HBP1, and GLIS2, attenuates pathologic hypertrophy, inhibits fibrosis of the heart tissue, and improves cardiac function via upregulation of its target gene, 26/March/2019, 11.13 pm

Repurposing the antibiotic Enoxacin into a broad-spectrum anti-infective agent: Enoxacin (Trade names: Comprecin, Enoksetin, Enoxen, Enroxil, Enoxin, Enoxor, Flumark and others),  a fluoroquinolone-based antibiotic commonly used in the treatment of urinary tract infections and gonorrhea,  inhibits Hepatitis-B/C, Dengue, Zika, Ebola, HIV-1, Mtb, Malaria, CMV, Influenza H1NI1,  respiratory syncytial,  Sindbis, and SFV viruses by increasing the Levels of the Antiviral Proteins IFITM3, & Interferon-stimulated gene 15, 26/March/2019, 10.38 pm
March 26, 2019
Repurposing the anti-bacterial agent Ciprofloxacin as an antiviral agent: Ciprofloxacin-based antiviral therapy for chikungunya (CHIKV) and Zika (ZIKV) viruses: Ciprofloxacin (brand name: Ciloxan, Cipro, Neofloxin) increases spermidine/spermine N1-acetyltransferase (SAT) expression, depletes spermidine and Spermine levels, and restricts Chikungunya and Zika viruses replication, via upregulation of its target gene, 26/March/2019, 11.23 pm
March 26, 2019
Show all

Introduction: What they say:  

A recent study from the Institute of Pharmacology and Toxicology, Technical University Munich (TUM), 80802, Munich, Germany; DZHK (German Center for Cardiovascular Research), partner site Munich Heart Alliance, 80802, Munich, Germany; and Mount Sinai, Cardiovascular Research Center, Icahn School of Medicine at Mount Sinai, New York, NY, 10029, USA shows that “Cardiac myocyte miR-29 promotes pathological remodeling of the heart by activating Wnt signaling.” This study was published, in the 20 November 2018 issue of the journal “Nature communications (One of the best journals in general science with an impact factor of 12+), by Prof Engelhardt, Sassi and others.


What we say:

On the foundation of this interesting finding, Dr L Boominathan PhD, Director-cum-chief Scientist of GBMD, reports that:Intracardiac  injection of Erythropoietin/Hematopoietin protects against cardiac hypertrophy and fibrosis: Intracardiac  injection of erythropoietin/hematopoietin decreases MiR-29 expression, activates wnt- signaling and its components GSK3B, ICAT/CTNNBIP1, HBP1, and GLIS2, attenuates pathologic hypertrophy, inhibits fibrosis of the heart tissue, and improves cardiac function via upregulation of its target gene

#


From the significance of the study to Public Health Relevance:

Given that: (1) cardiovascular disease is the leading cause of death worldwide; (2) the raise of death rate, due to cardiovascular disease, has increased from 123 lakhs in 1990 to 173 lakhs in 2013; (3) 85% of people over 80 years are susceptible to cardiovascular diseases;(4) in India, in 2004, 14.6 lakhs deaths (14% of total deaths) were due to ischemic heart disease; (3) the death due to cardiovascular disease is higher in low-to-middle income countries compared to developed countries; (4) the global economic cost spent in the treatment of cardiovascular disease in 2011 was little more than 10 billion US dollars; (5) an alarming number of people, such as 230 lakhs people, will die from cardiovascular diseases from 2030 onwards; (6) over 240 lakhs people suffer from heart failure globally, with only treatment option being the heart transplant, there is an urgent need to find: (i) a way to induce regeneration of cardiomyocytes that were lost in Myocardial patients; (ii) a cheaper alternative to the existing expensive drugs; and (iv) a side-effect-free Natural product-based drug.


What is known?

Cardiac stress, in long-term, has been shown to promote pathologic hypertrophy; and fibrosis of the myocardium. Recently, Prof. Engelhardt’s research team has shown that miRNA-29: (1) augments pathologic hypertrophy; (2) promotes cardiac dysfunction; and (3) deletion or antisense: (a) prevents cardiac hypertrophy; (b) prevents fibrosis; (c) activates the Wnt pathway components, such as GSK3B, ICAT/CTNNBIP1, HBP1 and GLIS2, suggesting that agents that decrease the expression of MiR-29 in adult cardiomyocytes may inhibit the Wnt pathway and improve cardiac function by attenuating cardiac hypertrophy and pathologic fibrosis.


From Research Findings to Therapeutic Opportunity:

Intracardiac injection of erythropoietin/hematopoietin, by increasing the expression of its target genes, it may decrease the expression of miR-29 (fig.1). Thereby, it may: (1) increase the expression of GSK3B, ICAT/CTNNBIP1, HBP1, and GLIS2; (2) inhibit the Wnt pathway; (3) increase the expression of a number of other gene products that attenuate cardiac hypertrophy and pathological fibrosis; and (4) prevent cardiac hypertrophy (fig 1). Thus, by subjecting cardiac patients to undergo erythropoietin/hematopoietin-based therapy, one may prevent pathological cardiac hypertrophy and fibrosis of the myocardium. Together, this study suggests, for the first time, that intracardiac injection of erythropoietin/hematopoietin, either alone or in combination with other cardioprotective drugs,” may be used to improve cardiac function.

Figure 1. Erythropoietin functions as a Cardioprotective agent. Mechanistic insights into how intracardiac injection of erythropoietin decreases the expression of MiR-29 and attenuates cardiac hypertrophy and fibrosis

Figure 2. Intracardiac injection of Erythropoietin attenuates cardiac hypertrophy and fibrosis through down-regulation of MiR-29 and up regulation of genes that promote cell cycle, including cyclins.

[easy_payment currency=”USD”]

Details of the research findings:

Idea Proposed/Formulated (with experimental evidence) by:

Dr L Boominathan Ph.D.

Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/

Undisclosed mechanistic information: How does intracardiac injection of erythropoietin/hematopoietin decrease the expression of MiR-29?

Amount: $750 #

# Research cooperation

For purchase and payment details, you may reach us at admin@genomediscovery.org


References:

Web:http://genomediscovery.org or http://newbioideas.com/

Citation: Boominathan, L., Intracardiac  injection of Erythropoietin/Hematopoietin protects against cardiac hypertrophy and fibrosis: Intracardiac  injection of erythropoietin/hematopoietin decreases MiR-29 expression, activates wnt- signaling and its components GSK3B, ICAT/CTNNBIP1, HBP1, and GLIS2, attenuates pathologic hypertrophy, inhibits fibrosis of the heart tissue, and improves cardiac function via upregulation of its target gene, 26/March/2019, 11.13 pm, Genome-2-BioMedicine Discovery center (GBMD), http://genomediscovery.org

Courtesy: When you cite drop us a line at admin@genomediscovery.org

Comments are closed.